J Vose

Summary

Affiliation: University of Nebraska Medical Center
Country: USA

Publications

  1. ncbi A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival
    Christine P Hans
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-3135, USA
    Blood 101:2363-7. 2003
  2. ncbi Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma
    Julie M Vose
    Department of Internal Medicine, Division of Hematology Oncology, University of Nebraska Medical Center, Omaha, Nebraska 68198 7680, USA
    Biol Blood Marrow Transplant 19:123-8. 2013
  3. ncbi Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project
    Massimo Federico
    Universita di Modena e Reggio Emilia, Modena, Italy
    J Clin Oncol 31:240-6. 2013
  4. ncbi Autotransplantation for mantle cell lymphoma
    Julie M Vose
    Division of Hematology Oncology, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE 98680, USA
    Cancer J 18:427-31. 2012
  5. ncbi Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management
    Julie M Vose
    Division of Hematology Oncology, University of Nebraska Medical Center, Omaha, NE 68198 7680, USA
    Am J Hematol 87:604-9. 2012
  6. ncbi Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission
    Julie M Vose
    University of Nebraska Medical Center, Omaha 68198 7680, USA
    Biol Blood Marrow Transplant 10:116-27. 2004
  7. ncbi Peripheral T-cell non-Hodgkin's lymphoma
    Julie M Vose
    Section of Hematology Oncology, Internal Medicine, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198 7680, USA
    Hematol Oncol Clin North Am 22:997-1005, x. 2008
  8. ncbi Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
    J M Vose
    University of Nebraska Medical Center, Omaha, NE 68198 7680, USA
    Leuk Lymphoma 46:1569-73. 2005
  9. ncbi Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach
    Julie M Vose
    Section of Oncology Hematology, University of Nebraska Medical Center, Omaha, NE 681980 7680, USA
    Hematol Oncol 24:47-55. 2006
  10. ncbi Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma
    Julie M Vose
    Section of Hematology Oncology, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Clin Oncol 23:461-7. 2005

Research Grants

  1. Nebraska Blood and Marrow Transplant Research Network
    Julie Vose; Fiscal Year: 2007

Detail Information

Publications85

  1. ncbi A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival
    Christine P Hans
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-3135, USA
    Blood 101:2363-7. 2003
    ..However, patients with FL3 having a diffuse component of more than 50% have an inferior survival that is similar to the survival of those with DLBCL...
  2. ncbi Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma
    Julie M Vose
    Department of Internal Medicine, Division of Hematology Oncology, University of Nebraska Medical Center, Omaha, Nebraska 68198 7680, USA
    Biol Blood Marrow Transplant 19:123-8. 2013
    ..A follow-up phase III trial with 131-Iodine tositumomab/BEAM vs rituximab/BEAM was planned based on this information...
  3. ncbi Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project
    Massimo Federico
    Universita di Modena e Reggio Emilia, Modena, Italy
    J Clin Oncol 31:240-6. 2013
    ..The International Peripheral T-Cell Lymphoma Project was undertaken to better understand the subtypes of T-cell and natural killer (NK) -cell lymphomas...
  4. ncbi Autotransplantation for mantle cell lymphoma
    Julie M Vose
    Division of Hematology Oncology, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE 98680, USA
    Cancer J 18:427-31. 2012
    ..However, the median age of patients with MCL is older than 60 years, which does not allow ASCT to be used in all patients with MCL. Research is now focused on reducing the relapse rate after transplantation...
  5. ncbi Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management
    Julie M Vose
    Division of Hematology Oncology, University of Nebraska Medical Center, Omaha, NE 68198 7680, USA
    Am J Hematol 87:604-9. 2012
    ..Autologous or allogeneic stem cell transplantation can also be considered in young patients...
  6. ncbi Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission
    Julie M Vose
    University of Nebraska Medical Center, Omaha 68198 7680, USA
    Biol Blood Marrow Transplant 10:116-27. 2004
    ..Exposure to myeloid growth factors to accelerate recovery for recipients of bone marrow grafts may increase the risk of disease progression or death...
  7. ncbi Peripheral T-cell non-Hodgkin's lymphoma
    Julie M Vose
    Section of Hematology Oncology, Internal Medicine, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198 7680, USA
    Hematol Oncol Clin North Am 22:997-1005, x. 2008
    ..The World Health Organization classification specifies 16 major subtypes of T-NHL. Each of the major subtype of peripheral T-NHL has unique characteristics and are addressed separately in this article...
  8. ncbi Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
    J M Vose
    University of Nebraska Medical Center, Omaha, NE 68198 7680, USA
    Leuk Lymphoma 46:1569-73. 2005
    ....
  9. ncbi Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach
    Julie M Vose
    Section of Oncology Hematology, University of Nebraska Medical Center, Omaha, NE 681980 7680, USA
    Hematol Oncol 24:47-55. 2006
    ..It is hoped that the results of these studies will lead to the incorporation of this promising approach into the standard treatment of patients with lymphoma...
  10. ncbi Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma
    Julie M Vose
    Section of Hematology Oncology, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Clin Oncol 23:461-7. 2005
    ....
  11. ncbi Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index
    Julie M Vose
    Department of Preventive and Societal Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198 7680, USA
    Biol Blood Marrow Transplant 14:36-42. 2008
    ..These data suggest that transplantation earlier in the course of the disease for patients with follicular lymphoma with use of a monoclonal antibody-based regimen may lead to improved outcomes...
  12. ncbi Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach
    Julie Vose
    Section of Oncology Hematology, University of Nebraska Medical Center, Omaha, NE 681980 7680, USA
    Clin Adv Hematol Oncol 3:923-32. 2005
    ..It is hoped that the results of these studies will lead to the incorporation of this promising approach into the standard treatment of patients with lymphoma...
  13. ncbi Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation
    Julie M Vose
    Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198 7680, USA
    Leuk Lymphoma 48:683-90. 2007
    ..A dose of 0.2 mCi/kg ibritumomab tiuxetan is safe and effective for patients with progressive disease after high-dose chemotherapy and ASCT...
  14. ncbi A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma
    Julie M Vose
    University of Nebraska Medical Center, Omaha, NE 68198 7680, USA
    Leuk Lymphoma 48:39-45. 2007
    ..Future studies will be needed to address modified dosing according to emerging pharmacokinetic and pharmacodynamic data and combination therapy which may lead to improved clinical benefit for troxacitabine in hematologic malignancies...
  15. ncbi Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma
    Julie M Vose
    Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198 7680, USA
    Oncologist 9:160-72. 2004
    ..Lymphomas are extremely sensitive to radiation, and significant progress has been made over the last decade in the development of radioimmunotherapy with anti-CD20 antibodies...
  16. ncbi Status of ongoing collaborative efforts
    Julie M Vose
    Division of Hematology Oncology, University of Nebraska Medical Center, Omaha, NE, USA
    Semin Hematol 47:S18-20. 2010
    ..As of October 2009, 479 patients from 13 centers were enrolled, and 454 of these cases were validated. The patients are evaluated for their responses to treatment, progression-free and overall survival, and treatments received...
  17. ncbi Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen
    Colin D Weekes
    University of Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Clin Oncol 20:1087-93. 2002
    ..Because of an improved side-effect profile, the regimen of chlorambucil, vinblastine, procarbazine, and prednisone (ChlVPP) has been proposed for use in elderly patients...
  18. ncbi Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with recurrent indolent non-Hodgkin's lymphoma
    J M Vose
    University of Nebraska Medical Center, Omaha 68198 7680, USA
    Biol Blood Marrow Transplant 7:680-7. 2001
    ....
  19. ncbi CNOP for diffuse aggressive non-Hodgkin's lymphoma: the Nebraska lymphoma study group experience
    Julie M Vose
    Section of Hematology Oncology, University of Nebraska Medical Center, Nebraska Medical Center, Omaha 68198 7680, USA
    Leuk Lymphoma 43:799-804. 2002
    ..However, patients of all ages who failed CNOP and who were able to receive HDC and ASCT demonstrated long-term disease survival after the transplant...
  20. ncbi Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
    J M Vose
    University of Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Clin Oncol 19:389-97. 2001
    ....
  21. ncbi Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease
    Julie M Vose
    Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 69198, USA
    J Clin Oncol 20:2344-52. 2002
    ....
  22. ncbi Advances in mobilization for the optimization of autologous stem cell transplantation
    Julie M Vose
    Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198 7680, USA
    Leuk Lymphoma 50:1412-21. 2009
    ..Recently, a new agent, plerixafor (AMD3100) added to G-CSF has been approved to enhance PBSC mobilization. This review will discuss the current methodologies to improve hematopoietic stem cell mobilization...
  23. ncbi Autologous hematopoietic stem cell transplantation for mantle cell lymphoma
    J M Vose
    Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198 7680, USA
    Biol Blood Marrow Transplant 6:640-5. 2000
    ..Whether this therapy will increase the overall survival or EFS in patients receiving transplants in first complete remission will need to be tested in prospective randomized clinical trials...
  24. ncbi Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma
    J M Vose
    Department of Internal Medicine, Nebraska Medical Center, Omaha 68198 7680, USA
    Leuk Lymphoma 38:91-101. 2000
    ..Non-hematologic toxicities were mild and few in number. Further evaluation of this treatment is warranted and further dose escalation will be possible...
  25. ncbi Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma
    J Vose
    University of Nebraska Medical Center, Omaha 68198-7680, USA
    Ann Oncol 14:i17-20. 2003
  26. ncbi Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma
    Kai Fu
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Clin Oncol 26:4587-94. 2008
    ..However, with the addition of rituximab to standard chemotherapy, the prognostic significance of this subclassification of DLBCL is unclear...
  27. ncbi A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy
    William W L Choi
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska 68198 3135, USA
    Clin Cancer Res 15:5494-502. 2009
    ..Since then, new antibodies specific to germinal center B-cells have been developed, which might improve the performance of an immunostain algorithm...
  28. ncbi Disparity in survival outcome after hematopoietic stem cell transplantation for hematologic malignancies according to area of primary residence
    Keshav Rao
    Brownell Talbot High School, Omaha, Nebraska, USA
    Biol Blood Marrow Transplant 13:1508-14. 2007
    ..Our findings suggest that the primary location of a patient's residence may be an independent risk factor for survival after HSCT...
  29. ncbi Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation
    Steven Z Pavletic
    Department of Internal Medicine, Section of Oncology Hematology, University of Nebraska Medical Center, Omaha, Nebraska, USA
    Am J Hematol 78:265-74. 2005
    ..More studies are needed to determine whether cGVHD prognostic systems should be used interchangeably in patient populations receiving different stem-cell products...
  30. ncbi Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma
    Marcel P Devetten
    University of Nebraska Medical Center, Omaha, Nebraska, USA
    Biol Blood Marrow Transplant 15:109-17. 2009
    ..Clinical studies should be aimed at reducing the incidence of acute graft-versus-host disease (GVHD) and relapse...
  31. ncbi Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group
    James Z Huang
    Department of Pathology, University of Nebraska Medical Center, Omaha, NE, USA
    Leuk Lymphoma 44:1903-10. 2003
    ..In conclusion, our findings suggest that patients with DLBCL arising in NLPHL have a prognosis similar to those with de novo DLBCL and should be treated aggressively...
  32. ncbi Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab
    Maribeth A Hohenstein
    Departments of Internal Medicine and Radiation Safety, and the College of Pharmacy, The University of Nebraska Medical Center, Omaha, NE 68198-7680, USA
    Semin Oncol 30:39-49. 2003
    ..These instructions ensure that radiation exposure of family members and caregivers who are exposed to the patient is maintained as low as reasonably achievable and well within regulatory limits...
  33. ncbi Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group
    James Z Huang
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA
    Leuk Lymphoma 45:1551-7. 2004
    ..Our findings suggest that patients with DLBCL arising in NLPHL have a prognosis similar to those with de novo DLBCL and should be treated aggressively...
  34. ncbi BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma
    Javeed Iqbal
    Department of Pathology and Microbiology, University of Nebraska Medical Center, 983135 Nebraska Medical Center, Omaha, NE 68198-3135, USA
    Am J Pathol 165:159-66. 2004
    ..However, despite this higher proliferative activity, there was no significant difference in overall or failure-free survival between the t(14;18)-positive and -negative subsets within the GCB subgroup...
  35. ncbi Hematopoietic stem cell transplantation for Hodgkin's disease in a patient with dysfibrinogenemia and thrombosis
    Apar Kishor Ganti
    Department of Internal Medicine, Section of Oncology Hematology, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Thromb Thrombolysis 23:155-8. 2007
    ..Management of patients with dysfibrinogenemia and a thrombotic tendency usually involves long-term anticoagulation...
  36. ncbi The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma
    Mary Lee H Villanueva
    Department of Internal Medicine, Section of Oncology Hematology, 987680 Nebraska Medical Center, Omaha, NE 68198, USA
    Clin Adv Hematol Oncol 4:521-30. 2006
    ..This review focuses on studies evaluating the role of stem cell transplantation in non-Hodgkin lymphoma...
  37. ncbi Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion
    Avadhut D Joshi
    Department of Genetics, Center for Research in Leukemia and Lymphoma, University of Nebraska Medical Center, Omaha, NE 68198 6395, USA
    Cancer Genet Cytogenet 172:120-6. 2007
    ..These results indicate an association between BLA and reduced expression of ATM, suggesting a role for ATM in disease progression in B-CLL...
  38. ncbi Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planning
    Apar Kishor Ganti
    University of Nebraska Medical Center, Section of Oncology Hematology, 987680 Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Clin Oncol 25:5643-8. 2007
    ..We conducted this analysis to determine if engagement in ACP among patients who undergo HSCT is associated with adverse outcomes...
  39. ncbi Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell products
    Rakesh K Singh
    Department of Pathology and Microbiology, University of Nebraska Medical Center 987660, Omaha, NE 68198 7660, USA
    Int Immunopharmacol 7:1033-43. 2007
    ....
  40. ncbi ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia
    Avadhut D Joshi
    Department of Genetics, Cell Biology, Center for Research in Leukemia and Lymphoma, University of Nebraska Medical Center, Omaha, Nebraska 68198 6395, USA
    Clin Cancer Res 13:5295-304. 2007
    ..However, the genes associated with CLL patient subgroups with high and low CD38 expression and their potential role in disease progression is not known...
  41. ncbi Current status of rituximab maintenance therapy
    Julie M Vose
    Section of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NB, USA
    Clin Adv Hematol Oncol 5:968-9,1006. 2007
  42. ncbi Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study
    Fausto R Loberiza
    Section of Oncology Hematology, Summer Undergraduate Research Program, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Clin Oncol 27:5376-82. 2009
    ....
  43. ncbi Lymphoma 2006: classification and treatment
    James O Armitage
    Section of Oncology Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198, USA
    Oncology (Williston Park) 20:231-9; discussion 242, 244, 249. 2006
    ....
  44. ncbi Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma
    Christine P Hans
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198 3135, USA
    Mod Pathol 18:1377-84. 2005
    ..035). Cyclin D2 and PKC-beta expression will be useful in designing a 'biological prognostic index' for patients with DLBCL...
  45. ncbi Follicular lymphoma: expanding therapeutic options
    Apar Kishor Ganti
    Department of Internal Medicine, University of Nebraska, Omaha, Nebraska, USA
    Oncology (Williston Park) 19:213-28; discussion 228, 233-6, 239. 2005
    ..Future directions in the treatment of follicular lymphoma include vaccines, antisense therapy, and proteasome inhibitors...
  46. ncbi Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood
    Philip J Bierman
    University of Nebraska Medical Center, Omaha, NE 68198 7680, USA
    J Clin Oncol 21:3744-53. 2003
    ..To compare results of syngeneic, allogeneic, and autologous hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma (NHL)...
  47. ncbi BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma
    Javeed Iqbal
    Leukemia/Lymphoma Molecular Profiling Project, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-3135, USA
    J Clin Oncol 24:961-8. 2006
    ..Hence, the significance of BCL2 and other biomarkers should be assessed in the context of DLBCL subgroups in future studies...
  48. ncbi Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma
    Timothy C Greiner
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA
    Proc Natl Acad Sci U S A 103:2352-7. 2006
    ..This information on molecular phenotypes may provide new areas of investigation for ATM function or may be exploited by designing specific therapies for MCL cases with p53 aberrations...
  49. ncbi Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice
    Samuel C Augustine
    Antibody Labeling Facility, University of Nebraska Medical Center, Omaha 68198 6045, USA
    J Am Pharm Assoc (Wash) 42:93-100. 2002
    ..To describe the application of pharmaceutical care practices in the administration of new therapeutic radiopharmaceuticals used in the treatment of non-Hodgkin's lymphoma (NHL)...
  50. ncbi Prognostic factors influencing survival in patients with B-cell small lymphocytic lymphoma
    Marin Nola
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska, USA
    Am J Hematol 77:31-5. 2004
    ..In multivariate analysis, the IPI score was the only significant predictor of OS. Anemia and B symptoms were additionally predictive of poor OS in patients with low IPI scores...
  51. ncbi Effect of linkage of transduction domain sequences to a lymphoma idiotype DNA vaccine on vaccine effectiveness
    Abdel-Kader Ashour
    Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska 68198-6805, USA
    Hybridoma (Larchmt) 25:306-8. 2006
    ..Thus, the addition to idiotype vaccines of specific sequences that facilitate intracellular transport may have potential to improve the effectiveness of such vaccines...
  52. ncbi Revised response criteria for malignant lymphoma
    Bruce D Cheson
    Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    J Clin Oncol 25:579-86. 2007
    ..Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies...
  53. ncbi Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma
    Ganapati V Hegde
    Department of Genetics, Cell Biology, and Anatomy, Center for Research in Leukemia and Lymphoma, University of Nebraska Medical Center, Omaha, NE 68198 6395, USA
    Mol Cancer Ther 7:1450-60. 2008
    ..Thus, our results indicate a significant role for Shh-GLI signaling in the proliferation of MCL, and molecular targeting of GLI is a potential therapeutic approach to improve the treatment for MCL...
  54. ncbi Dendritic cell-based therapy for mantle cell lymphoma
    Corey M Munger
    Department of Genetics, University of Nebraska Medical Center, Omaha, NE 68198-6395, USA
    Int J Oncol 28:1337-43. 2006
    ..Histological analysis of liver from control and treated mice displayed a decrease in the number of the tumor nodules in the treatment group. These results indicate the potential of DC-based therapy for the treatment of MCL...
  55. ncbi Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro
    J Iqbal
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198 3135, USA
    Leukemia 25:348-58. 2011
    ....
  56. ncbi Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation
    Steven Z Pavletic
    Department of Internal Medicine, Section of Oncology Hematology, University of Nebraska Medical Center, Omaha, NE, USA
    Transplantation 76:877-81. 2003
    ..5% donor CD3 lymphocytes. PT demonstrated lymphodepleting effects and promising safety, supporting alloNST as early as 7 days after initiation of PT...
  57. ncbi Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target
    Ganapati V Hegde
    Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE 68198 6395, USA
    Mol Cancer Res 6:1928-36. 2008
    ..Together, these results reveal that Hh signaling is important in the pathogenesis of B-CLL and, hence, may be a potential therapeutic target...
  58. ncbi Update on lymphoma management: diffuse large B-cell NHL
    Julie M Vose
    Section of Hematology/Oncology, University of Nebraska Medical Center, Omaha, Nebraska, USA
    Hematology 10:10-4. 2005
  59. ncbi Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma
    Javeed Iqbal
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198 3135, USA
    Blood 115:1026-36. 2010
    ..Oncogenic pathways and tumor-host interactions also were identified, and these findings may lead to better therapies and outcome in the future...
  60. ncbi The role of hematopoietic stem cell transplant in follicular lymphoma
    Edward A Faber
    University of Nebraska Medical Center, Omaha, Nebraska 68198 7680, USA
    J Natl Compr Canc Netw 8:337-44; quiz 345. 2010
    ....
  61. ncbi Graft-versus-host disease: how to translate new insights into new therapeutic strategies
    Marcel P Devetten
    University of Nebraska, 987680 Nebraska Medical Center, Omaha, NE 68198-7680, USA
    Biol Blood Marrow Transplant 10:815-25. 2004
    ..We review each phase in the development of acute GVHD and discuss recently developed interventions aimed to prevent or treat GVHD by interfering with these pathways...
  62. ncbi Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
    Andres Forero
    University of Alabama at Birmingham Comprehensive Cancer Center, 35294 3300, USA
    Blood 104:227-36. 2004
    ..B9E9FP performs well as the targeting component of PRIT with encouraging dosimetry, safety, and efficacy. A dose escalation trial of (90)Y-DOTA-biotin in this format is warranted...
  63. ncbi R-DHAP: a good small step, but not the journey's end
    Peter McLaughlin
    Department of Lymphoma and Myeloma, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 49:1019-21. 2008
  64. ncbi A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma
    John E Levine
    University of Michigan Medical Center, Ann Arbor, USA
    Blood 101:2476-82. 2003
    ..In summary, alloSC transplantation for LBL is associated with fewer relapses than with autoSC transplantation, but higher TRM offsets any potential survival benefit...
  65. ncbi Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease
    Francis J Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 123:850-7. 2003
    ..The clinical significance of circulating antigen in patients receiving monoclonal antibody therapy directed against CD20 and/or CD52 warrants study...
  66. ncbi Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries
    Elisabeth Vandenberghe
    Department of Haematology, St James Hospital, Dublin, Ireland
    Br J Haematol 120:793-800. 2003
    ..99 times (95% CI: 1.66-5.38, P < 0.001) more likely to die than patients transplanted in CR1. Autologous transplantation probably improves survival in patients with MCL especially if performed in first CR...
  67. ncbi Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma
    Nicole Y Fang
    Genome Technology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:5372-7. 2003
    ..mutated ATM in MCL. Additional mutational and functional analyses are needed to determine whether ATM mutations contribute to the development and progression of MCL or are just the consequence of genomic instability in MCL...
  68. ncbi Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma
    Koen Van Besien
    Lymphoma Working Committee, International Bone Marrow Transplant Registry Autologous Blood and Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, USA
    Blood 102:3521-9. 2003
    ..We did not detect a correlation between graft-versus-host disease (GVHD) and recurrence. Finally, outcomes of transplantation for follicular lymphoma show improvement over the past decade...
  69. ncbi Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma
    Francis J Giles
    Department of Leukemia, MD Anderson Cancer Center, The University of Texas, PO Box 428, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Res 28:595-604. 2004
    ..In patients with NHL, post-therapy levels of angiogenin were independently predictive of survival. Both pre-therapy and post-therapy VEGF levels were independently predictive of survival in patients with HD...
  70. ncbi Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant
    Sonali M Smith
    Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA
    Biol Blood Marrow Transplant 14:904-12. 2008
    ..HCT2 should be considered for patients with relapsed HL or NHL after HCT1 without alternative allogeneic stem cell transplant options...
  71. ncbi Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma
    Peter H Wiernik
    Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY, USA
    J Clin Oncol 26:4952-7. 2008
    ..We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL...
  72. ncbi Advances in the treatment of hematologic malignancies. Part 1 of a 3-part series: Aggressive lymphomas
    Richard I Fisher
    James P. Wilmot Cancer Center, University of Rochester, NY, USA
    Clin Adv Hematol Oncol 4:suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10. 2006
    ..Recent and ongoing studies are moving us closer towards that goal...
  73. ncbi Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project
    Charles L Bennett
    VA Midwest Center for Health Services and Policy Research, the Jesse Brown VA Medical Center, Chicago, IL, USA
    Br J Haematol 135:642-50. 2006
    ..While a causal relationship with haematological malignancies cannot be demonstrated, long-term follow-up among healthy individuals who receive haematopoietic growth factors is needed...
  74. ncbi Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease
    Maher Albitar
    Quest Diagnostics Nichols Institute, 33608 Ortega Highway, Rm 108B, San Juan Capistrano, CA 92690 6130, United States
    Leuk Res 31:139-45. 2007
    ..Further studies are needed to assess whether the immunomodulatory properties of sHLA-I may be responsible for its divergence from beta2M as an indicator of clinical behavior in HD...
  75. ncbi Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation
    Willis H Navarro
    University of California, San Francisco, San Francisco, California 94080 4990, and University Hospitals of Cleveland, OH, USA
    Biol Blood Marrow Transplant 12:541-51. 2006
    ....
  76. ncbi Multiple myeloma. Clinical practice guidelines in oncology
    Kenneth C Anderson
    J Natl Compr Canc Netw 5:118-47. 2007
  77. ncbi Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas
    Richard I Fisher
    University of Rochester School of Medicine, James P Wilmot Cancer Center, 601 Elmwood Ave, Box 704, Rochester, NY 14642, USA
    J Clin Oncol 23:7565-73. 2005
    ....
  78. ncbi Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma
    Myron S Czuczman
    Roswell Park Cancer Institute, Elm and Carlton St, Buffalo, NY 14263 0001, USA
    J Clin Oncol 23:4390-8. 2005
    ..This multicenter, dose-escalation study evaluates the safety, pharmacokinetics, and efficacy of galiximab (anti-CD80 monoclonal antibody) in patients with relapsed or refractory follicular lymphoma...
  79. ncbi Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab
    John M Bennett
    James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, NY 14642, USA
    Blood 105:4576-82. 2005
    ..With a median follow-up approaching 5 years, no case of tMDS/tAML has been reported in any of the 76 patients receiving iodine I(131) tositumomab as their initial therapy (P = .011 compared with previously treated patients)...
  80. ncbi Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning
    Parameswaran Hari
    Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    Biol Blood Marrow Transplant 14:236-45. 2008
    ..Although disease-free survival (DPS) is similar compared to myeloablative conditioning, an increased risk of late disease progression after RIC is concerning...
  81. ncbi Non-Hodgkin's lymphomas
    Andrew D Zelenetz
    J Natl Compr Canc Netw 6:356-421. 2008
  82. ncbi Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry
    Cesar O Freytes
    University of Texas Health Science Center, Mail Code 7880, 7703 Floyd Curl Dr, San Antonio, TX 78229 3900, USA
    Blood 104:3797-803. 2004
    ..Most likely to benefit are patients who have HLA-matched sibling donors, are in remission, and have good performance status...
  83. ncbi Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study
    Ken H Young
    Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, University of of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, USA
    Blood 112:3088-98. 2008
    ..This study shows the prognostic importance of mutations in the TP53 DNA-binding domains in patients with DLBCL...
  84. ncbi Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY 10021, USA
    Clin Adv Hematol Oncol 6:437-45. 2008
    ..This review focuses on the development of novel therapies for rituximab-pretreated, relapsed or refractory indolent NHL...
  85. ncbi Molecular diagnosis of Burkitt's lymphoma
    Sandeep S Dave
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    N Engl J Med 354:2431-42. 2006
    ..CONCLUSIONS: Gene-expression profiling is an accurate, quantitative method for distinguishing Burkitt's lymphoma from diffuse large-B-cell lymphoma...

Research Grants2

  1. Nebraska Blood and Marrow Transplant Research Network
    Julie Vose; Fiscal Year: 2007
    ..End of abstract.) ..